Sagimet Biosciences director granted 39,567 options

Sagimet Biosciences Inc. director Jennifer Jarrett reported a grant of stock options on Series A Common Stock.

Rhea-AI Filing Summary

Sagimet Biosciences Inc. director Jennifer Jarrett reported a grant of stock options on Series A Common Stock. She received options for 39,567 shares at an exercise price of $6.48 per share, all held as a direct derivative position following the transaction.

According to the terms, the shares underlying this option will vest and become exercisable in twelve equal monthly installments following June 12, 2026, conditioned on her continued service on each vesting date. The option expires on June 11, 2036, providing a long-dated equity incentive aligned with her board role.

Insider Trade Summary

Grant/Award: 39,567 shares

Grant/Award 1 txn

Insider Jarrett Jennifer

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	39,567	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 39,567 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Option grant size: 39,567 shares Exercise price: $6.48 per share Post-transaction derivative holdings: 39,567 options +2 more

5 metrics

Option grant size 39,567 shares Stock Option (Right to Buy) on Series A Common Stock

Exercise price $6.48 per share Conversion or exercise price of granted options

Post-transaction derivative holdings 39,567 options Total derivative securities following the transaction

Vesting schedule length 12 monthly installments Vesting begins after June 12, 2026

Option expiration date June 11, 2036 Expiration of stock option grant

Key Terms

Stock Option (Right to Buy), Series A Common Stock, exercise price, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Series A Common Stock financial

"underlying_security_title: Series A Common Stock"

Series A common stock is a specific class of a company’s ordinary shares issued during an early formal funding round, carrying the ownership rights and voting power tied to that class. For investors it signals an early-stage equity claim with potential upside if the business grows, but also greater risk and typically less liquidity than shares in mature, publicly traded firms—imagine buying a seat on a startup’s team before the company has proven itself.

exercise price financial

"conversion_or_exercise_price: 6.4800 per share as exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares underlying this option shall vest and become exercisable over twelve monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Sagimet Biosciences (SGMT) director Jennifer Jarrett report on this Form 4?

Jennifer Jarrett reported receiving a stock option grant for 39,567 shares of Sagimet Biosciences Series A Common Stock. The award is a derivative security, providing the right to buy shares at a fixed exercise price under specified vesting terms.

How many Sagimet Biosciences (SGMT) options did Jennifer Jarrett receive and at what exercise price?

She received options covering 39,567 shares with an exercise price of $6.48 per share. These options give her the right to purchase Series A Common Stock at that price if and when the underlying shares vest and the option is exercised.

What is the vesting schedule for Jennifer Jarrett’s Sagimet (SGMT) stock options?

The shares underlying the option vest in twelve equal monthly installments following June 12, 2026. Vesting on each monthly date is subject to her continued service, meaning she must remain in her role to earn each additional portion of the grant.

When do Jennifer Jarrett’s Sagimet Biosciences (SGMT) options expire?

The stock options expire on June 11, 2036. After that expiration date, any unexercised portion of the option will lapse, and she will no longer have the right to purchase the related shares at the $6.48 exercise price.

How many Sagimet Biosciences (SGMT) derivative securities does Jennifer Jarrett hold after this transaction?

Following this reported transaction, she holds 39,567 derivative securities in the form of stock options. This entire position comes from the newly granted options, which are subject to the specified vesting and expiration terms described in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jarrett Jennifer

(Last) (First) (Middle)

SAGIMET BIOSCIENCES INC.

155 BOVET ROAD, SUITE 303

(Street)

SAN MATEO CALIFORNIA 94402

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sagimet Biosciences Inc. [ SGMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.48	06/12/2026		A		39,567		(1)	06/11/2036	Series A Common Stock	39,567	$0	39,567	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Elizabeth Rozek, Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)